DE69332982D1 - Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung - Google Patents

Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung

Info

Publication number
DE69332982D1
DE69332982D1 DE69332982T DE69332982T DE69332982D1 DE 69332982 D1 DE69332982 D1 DE 69332982D1 DE 69332982 T DE69332982 T DE 69332982T DE 69332982 T DE69332982 T DE 69332982T DE 69332982 D1 DE69332982 D1 DE 69332982D1
Authority
DE
Germany
Prior art keywords
thymosine
decomposed
patients
alpha
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332982T
Other languages
English (en)
Other versions
DE69332982T2 (de
Inventor
Paul B Chretien
Milton G Mutchnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Alpha 1 Biomedicals Inc filed Critical Wayne State University
Priority claimed from PCT/US1993/010619 external-priority patent/WO1995012405A1/en
Application granted granted Critical
Publication of DE69332982D1 publication Critical patent/DE69332982D1/de
Publication of DE69332982T2 publication Critical patent/DE69332982T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69332982T 1993-11-05 1993-11-05 Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung Expired - Fee Related DE69332982T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/010619 WO1995012405A1 (en) 1993-11-05 1993-11-05 Method and composition for treatment of patients having decompensated liver disease

Publications (2)

Publication Number Publication Date
DE69332982D1 true DE69332982D1 (de) 2003-06-18
DE69332982T2 DE69332982T2 (de) 2004-09-09

Family

ID=22237139

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332982T Expired - Fee Related DE69332982T2 (de) 1993-11-05 1993-11-05 Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung

Country Status (11)

Country Link
EP (1) EP0731710B1 (de)
KR (1) KR100298859B1 (de)
CA (1) CA2175337C (de)
DE (1) DE69332982T2 (de)
DK (1) DK0731710T3 (de)
ES (1) ES2194860T3 (de)
HK (1) HK1021685A1 (de)
MX (1) MXPA94003453A (de)
MY (1) MY111342A (de)
NO (1) NO961775D0 (de)
PT (1) PT731710E (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b

Also Published As

Publication number Publication date
CA2175337C (en) 2000-06-20
DK0731710T3 (da) 2003-06-16
KR100298859B1 (ko) 2001-10-22
KR960706352A (ko) 1996-12-09
DE69332982T2 (de) 2004-09-09
MXPA94003453A (es) 2004-08-16
EP0731710B1 (de) 2003-05-14
ES2194860T3 (es) 2003-12-01
NO961775L (no) 1996-05-02
CA2175337A1 (en) 1995-05-11
EP0731710A1 (de) 1996-09-18
EP0731710A4 (de) 1999-12-22
HK1021685A1 (en) 2000-06-23
PT731710E (pt) 2003-09-30
MY111342A (en) 1999-11-30
NO961775D0 (no) 1996-05-02

Similar Documents

Publication Publication Date Title
DE59408901D1 (de) Verfahren zur Herstellung von Polyacetalen
DE69424522D1 (de) Methode zur resuspendierung von zellreichen konzentraten
ATE112963T1 (de) Gewebeentzusammensetzung und verfahren.
DE68918142D1 (de) Zusammensetzungen und Verfahren zur kontrollierten Freisetzung von Duftstoffen.
DE59402624D1 (de) Verfahren zur Herstellung von Cycloolefincopolymeren
DE69008456D1 (de) Filmzusammensetzung zur Behandlung von Oberflächen und Verfahren zu ihrer Herstellung.
ATA253990A (de) Konzentrierte fungizide mittel und verfahren zur herstellung solcher granulierter mittel
DE69128362D1 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE69314962D1 (de) Verfahren zur entkeimung von lebensmitteln
DE69222735D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kühlwasser
DE59400779D1 (de) Verfahren zur Herstellung von Hexafluorbuten
DE69231592D1 (de) Verfahren und zusammensetzungen zur behandlung von malaria und anderen erkrankungen
DE69428273D1 (de) Verfahren zur Behandlung von festen Abfällen
MX9100051A (es) Mezcla esterilizante y metodo de esterilizacion
DE59402794D1 (de) Strahlungsempfindliches Gemisch und Verfahren zur Herstellung von Reliefstrukturen mit verbessertem Kontrast
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
DE69414660D1 (de) Prozess zur Verminderung von Abfällen bei der Herstellung von Acrylnitril
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ATA4491A (de) Verfahren zur bekämpfung von unkräutern in maisfeldern
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
DE69030584D1 (de) Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral
DE68900892D1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.
DE59308384D1 (de) Verfahren zur Behandlung von Gülle
DE69332982D1 (de) Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SCICLONE PHARMACEUTICALS, INC., SAN MATEO, CALIF.,

8332 No legal effect for de
8370 Indication of lapse of patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee